Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
7.71
+0.07 (0.92%)
At close: May 8, 2026, 4:00 PM EDT
7.71
0.00 (0.01%)
After-hours: May 8, 2026, 7:25 PM EDT
Sagimet Biosciences Stock Forecast
Stock Price Forecast
The 8 analysts that cover Sagimet Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $28.75, which forecasts a 272.89% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $49.
Price Target: $28.75 (+272.89%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sagimet Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 5 | 5 |
| Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $28 → $49 | Strong Buy | Maintains | $28 → $49 | +535.54% | May 4, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $27 → $25 | Strong Buy | Maintains | $27 → $25 | +224.25% | Apr 29, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +276.13% | Mar 11, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +250.19% | Feb 3, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +276.13% | Feb 3, 2026 |
Financial Forecast
Revenue This Year
3.74M
Revenue Next Year
782.00K
from 3.74M
Decreased by -79.09%
EPS This Year
-1.37
from -1.58
EPS Next Year
-1.45
from -1.37
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 34.7M | 5.3M | ||||||
| Avg | 3.7M | 782,003 | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 40.4% | ||||||
| Avg | - | -79.1% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.87 | -0.78 | ||||||
| Avg | -1.37 | -1.45 | ||||||
| Low | -1.96 | -1.96 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.